B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Top Cited Papers
Open Access
- 25 March 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 15 (1), S3-8
- https://doi.org/10.1186/ar3908
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- B cell biomarkers of rituximab responses in systemic lupus erythematosusArthritis & Rheumatism, 2011
- The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximabVaccine, 2011
- Pivotal Advance: CD45RB glycosylation is specifically regulated during human peripheral B cell differentiationJournal of Leukocyte Biology, 2011
- Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cellsBlood, 2010
- Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndromeArthritis & Rheumatism, 2009
- The human spleen is a major reservoir for long-lived vaccinia virus–specific memory B cellsBlood, 2008
- Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximabAnnals Of The Rheumatic Diseases, 2007
- Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune DiseasesImmunobiology, 2002
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.1994
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.1994